Preparation of 188Re-RC-160 somatostatin analog: a peptide for local/regional radiotherapy.
Conditions are described for the preparation of 188Re-RC-160, a radiolabeled synthetic peptide derived from an analogue of somatostatin, using a lyophilized labeling kit containing RC-160 (200 micrograms) and stannous tartrate to which is added carrier-free 188Re (beta, Emax, 2.12 MeV; gamma, 155 keV, 10%; T1/2 = 16.7 h). The kits have been radiolabeled with > 2960 MBq (80 mCi) with a high labeling efficiency and no need for subsequent purification. Radiolabeling results in one major peak when analyzed by reverse-phase (RP) HPLC. Presumptive radiolysis was detected at 2.5 h post-labeling; however, a convenient method is described for stabilizing the kits against radiolysis by the post-labeling addition of ascorbic acid.
Zamora
P O
PO
RhoMed Inc., Albuquerque, NM 87109, USA.
Marek
M J
MJ
Knapp
F F
FF
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D007553:Isotope Labeling / Q000379:methods*; D010084:Oxidation-Reduction; D011868:Radioisotopes / Q000737:chemistry* / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods; D011933:Reagent Kits, Diagnostic; D012211:Rhenium / Q000737:chemistry* / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D017971:Tin Compounds / Q000737:chemistry
D000970:Antineoplastic Agents; D011868:Radioisotopes; D011933:Reagent Kits, Diagnostic; D017971:Tin Compounds; C051458:vapreotide; D013004:Somatostatin; D012211:Rhenium